Platelets, arterial thrombosis and cerebral ischemia

Cerebrovascular Diseases

Volumn 24, Issue SUPPL. 1, 2007, Pages 30-39

  Badimon, Lina ^a,b   Vilahur, Gemma ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b Institut Català de Ciències Cardiovasculars   (Spain)

Author keywords

Atherosclerotic plaque; Atherothrombosis; Platelet; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE;

ADULTHOOD; ARTERY BLOOD FLOW; ARTERY DISEASE; ARTERY THROMBOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; BLOOD VESSEL OCCLUSION; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE COURSE; EMBOLISM; HUMAN; INCIDENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYSTEMIC DISEASE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

ANIMALS; BLOOD PLATELETS; BRAIN ISCHEMIA; CEREBRAL ARTERIES; HUMANS; INTRACRANIAL THROMBOSIS; STROKE;

EID: 35648929824     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107377     Document Type: Conference Paper

References (62)

1. Badimon L, Martinez-Gonzalez J, Llorente-Cortes V, Rodriguez C, Padro T: Cell biology and lipoproteins in atherosclerosis. Curr Mol Med 2006;6:439-456.
2. Badimon L, Chesebro JH, Badimon JJ: Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. Circulation 1992;86:III74-III85.
3. Badimon L, Vilahur G, Sanchez S, Duran X: Atheromatous plaque formation and thrombogenesis: formation, risk factors and therapeutic approaches. Eur Heart J Suppl 2001;3:I16-I22.
4. Badimon L, Badimon J, Vilahur G, Segales E, Llorente V: Pathogenesis of the acute coronary syndromes and therapeutic implications. Pathophysiol Haemost Thromb 2002;32:225-231.
5. Ross R: Atherosclerosis as inflammatory disease. N Engl J Med 1999;340:115-126.
6. Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull W Jr, Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, et al: A definition of the intima of human arteries and of its atherosclerosis-prone regions: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb 1992;12:120-134.
7. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM: Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:1262-1275.
8. Schaar JA, Muller JE, Falk E: Terminology for high-risk and vulnerable coronary artery plaques: report of a meeting on the vulnerable plaque. Eur Heart J 2003;25:1077-1082.
9. Gnasso A, Irace C, Carallo C, De Franceschi MS, Motti C, Mattioli PL, Pujia A: In vivo association between low wall shear stress and plaque in subjects with asymmetrical carotid atherosclerosis. Stroke 1997;28:993-998.
10. Asakura T, Karino T: Flow patterns and spatial distribution of atherosclerotic lesions in human coronary arteries. Circ Res 1990;66:1045-1066.
11. Pedersen EM, Agerbaek M, Kristensen IB, Yoganathan AP: Wall shear stress and early atherosclerotic lesions in the abdominal aorta in young adults. Eur J Vasc Endovasc Surg 1997;13:443-451.
12. Michiels C: Endothelial cell functions. J Cell Physiol 2003;196:430-443.
13. Massberg S, Gruner S, Konrad I, Garcia Arguinzonis MI, Eigenthaler M, Hemler K, Kersting J, Schulz C, Muller I, Besta F, Nieswandt B, Heinzmann U, Walter U, Gawaz M: Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. Blood 2004;103:136-142.
14. Faggiotto A, Ross R: Studies of hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque. Arteriosclerosis 1984;4:341-356.
15. Nityanand S, Pande I, Bajpai VK, Singh L, Chandra M, Singh BN: Platelets in essential hypertension. Thromb Res 1993;72:447-454.
16. Broijersen A, Karpe F, Hamsten A, Goodall AH, Hjemdahl P: Alimentary lipemia enhances the membrane expression of platelet P-selectin without affecting other markers of platelet activation. Atherosclerosis 1998;137:107-113.
17. Nowak J, Murray JJ, Oates JA, Fitzgerald GA: Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 1987;76:6-14.
18. Manduteanu I, Calb M, Lupu C, Simionescu N, Simionescu M: Increased adhesion of human diabetic platelets to cultured valvular endothelial cells. J Submicrosc Cytol Pathol 1992;24:539-547.
19. Huo Y, Ley KF: Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 2004;14:18-22.
20. Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M: A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002;196:887-896.
21. Stenberg P, McEver R, Shuman M, Jacques Y, Bainton DF: A platelet alpha granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985;101:880-886.
22. Furman M, Benoit S, Barnard M, et al: Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998;31:352-358.
23. Merten M, Thiagarajan P: P-selectin in arterial thrombosis. Z Kardiol 2004;93:855-863.
24. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-594.
25. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML: Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-1111.
26. Ruggeri ZM: Von Willebrand factor. J Clin Invest 1997;99:559-564.
27. Savage B, Saldivar E, Ruggeri ZM: Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996;84:657-666.
28. Massberg S, Shulz C, Gawaz M: Role of platelets in the pathophysiology of acute coronary syndrome. Semin Vasc Med 2003;3:147-161.
29. Gibbins J, Okuma M, Farndale R, Barnes M, Watson S: Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gammachain. FEBS Lett 1997;413:255-259.
30. Nieswandt B, Brakebush C, Bergmeier Wea: Glycoprotein VI but not α2β1 integrin is essential for platelet interaction with collagen. EMBO J 2001;20:2120-2130.
31. Sixma JJ, Hindriks G, Van Breugel H, Hantgan R, de Groot PG: Vessel wall proteins adhesive for platelets. J Biomater Sci Polym Ed 1991;3:17-26.
32. Houdijk WP, Sakariassen KS, Nievelstein PF, Sixma JJ: Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III. J Clin Invest 1985;75:531-540.
33. Cattaneo M, Gachet C: ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999;192:2281-2285.
34. Moons A, Levi M, Peters R: Tissue factor and coronary artery disease. Cardiovasc Res 2002;53:313-325.
35. Viles-Gonzalez JF, Fuster V, Badimon JJ: Links between inflammation and thrombogenicity in atherosclerosis. Curr Mol Med 2006;6:489-499.
36. Lefkovits J, Topol E: Role of platelet inhibitor agents in coronary artery disease;in Topol EJ (ed): Textbook of Interventional Cardiology. Philadelphia, Saunders, 1999, pp 3-24.
37. Vu TK, Hung DT, Wheaton VI, Coughlin SR: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057-1068.
38. Leger A, Lidija C, Kuliopulos A: Protease-activated receptors in cardiovascular diseases. Circulation 2006;114:1070-1077.
39. Covic L, Gresser A, Kuliopulos A: Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 2000;39:5458-5467.
40. Johnston SC: Clinical practice. Transient ischemic attack. N Engl J Med 2002;347:1687-1692.
41. Johnson R, Griftin J, Mcarthur J: Current Therapy in Neurologic Disease, ed 6. St Louis, Mosby, 2002.
42. Group TNIoNDaSr-PSS: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
43. Association NS: Stroke/brain attack briefing. Englewood, Postgraduate Institute for Medicine, 1996.
44. Schulz UG, Rothwell PM: Association between arterial bifurcation anatomy and angiographic plaque ulceration among 4,627 carotid stenoses. Cerebrovasc Dis 2003;15:244-251.
45. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, Rankin RN, Clagett GP, Hachinski VC, Sackett DL, Thorpe KE, Meldrum HE, Spence JD: Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998;339:1415-1425.
46. Krupinski J, Catena E, Miguel M, Domenech P, Vila R, Morchon S, Rubio F, Cairols M, Slevin M, Badimon L: D-dimer local expression is increased in symptomatic patients undergoing carotid endarterectomy. Int J Cardiol 2007;116:174-179.
47. Wolf P, Abbot R, Kannel W: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988.
48. Wolff V, Aleil B, Giroud M, Lorenzini JL, Meyer N, Wiesel ML, Cazenave JP, Lanza F: Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke. Stroke 2005;36:e17-e19.
49. Chamorro Á: Role of inflammation in stroke and atherothrombosis. Cerebrovasc Dis 2004;17(suppl 3):1-5.
50. Gabay C KI: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454.
51. Ridker PM: Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum. Circulation 2002;105:2583-2258.
52. Krupinski J, Turu MM, Martinez-Gonzalez J, Carvajal A, Juan-Babot JO, Iborra E, Slevin M, Rubio F, Badimon L: Endogenous expression of C-reactive protein is increased in active (ulcerated noncomplicated) human carotid artery plaques. Stroke 2006;37:1200-1204.
53. Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abilleira S, Arenillas J, Gonzalez MA, Monasterio J: Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001;32:1759-1766.
54. Turu MM, Krupinski J, Catena E, Rosell A, Montaner J, Rubio F, Alvarez-Sabin J, Cairols M, Badimon L: Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis 2006;187:161-169.
55. Slevin M, Elasbali AB, Turu MM, Krupinski J, Badimon L, Gaffney J: Identification of differential protein expression associated with development of unstable human carotid plaques. Am J Pathol 2006;168:1004-1021.
56. Sacco RL, Chong JY, Prabhakaran S, Elkind MS: Experimental treatments for acute ischaemic stroke. Lancet 2007;369:331-341.
57. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P: Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2004;126:483S-512S.
58. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
59. CAPRIE Steering Committee: A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
60. Diener HC: Aspirin therapy should be firstline treatment in secondary prevention of stroke - against. Stroke 2002;33:2138-2139.
61. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-337.
62. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559.